SCHEMBL4796320

SCHEMBL4796320

CSc1ncnc2sc(-c3c(-c4ccccc4)ncn3C)nc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEK Q02763 11/20 0.72
FLT1 P17948 4/20 0.72
KDR P35968 4/20 0.72
NSD3 Q9BZ95 1/20 0.43
IKBKB O14920 2/20 0.40
CHUK O15111 1/20 0.40
TNIK Q9UKE5 1/20 0.35
NTRK1 P04629 1/20 0.34
NSD2 O96028 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
POLB P06746 1/20 0.32
TSHR P16473 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PIP4K2C Q8TBX8 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4799773 0.86 TEK (0.74) TEKFLT1KDRIKBKBCHUK
SCHEMBL4801626 0.85 TEK (0.58) TEKFLT1KDRNSD3IKBKB
SCHEMBL4798243 0.84 TEK (0.75) TEKFLT1KDRNSD3IKBKB
SCHEMBL4798753 0.84 TEK (1.00) TEKFLT1KDRNSD3IKBKB
SCHEMBL4796009 0.83 TEK (0.50) TEKFLT1KDRIKBKBCHUK
SCHEMBL4798366 0.83 TEK (0.73) TEKFLT1KDRNSD3IKBKB
SCHEMBL4796348 0.82 TEK (0.49) TEKFLT1KDRIKBKBCHUK
SCHEMBL4796261 0.79 TEK (0.75) TEKFLT1KDRNPSR1MEN1
SCHEMBL4796150 0.77 TEK (0.72) TEKFLT1KDRNSD3NPSR1
SCHEMBL4795815 0.77 TEK (0.64) TEKFLT1KDRNSD3IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7427616-B2 Condensed pyridines and pyrimidines with tie2 (TEK) activity ASTRAZENECA AB (SE) 2008-09-23 US disclosed
EP-1537112-B1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2006-04-19 EP disclosed
US-20050256140-A1 Condensed pyridines and pyrimidines with tie2 (tek) activity ASTRAZENECA AB (SE) 2005-11-17 US disclosed
EP-1537112-A1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY Astrazeneca AB (SE) 2005-06-08 EP disclosed
WO-2004013141-A1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2004-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256140-A1 Condensed pyridines and pyrimidines with tie2 (tek) activity TIE1, TEK, KDR TEK 2/4885FLT1 6/4885KDR 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.